for motion sickness
FDA approved Nereus (tradipitant) for motion sickness on May 4, 2026 — the first new pharmacologic treatment for motion sickness in over 40 years. Distinct program from Vanda's tradipitant gastroparesis NDA which received a CRL earlier.
Motion sickness is a condition where the brain's perception of motion doesn't match what the body senses, causing distressing symptoms like nausea, vomiting, and dizziness. Nereus (tradipitant) is an oral drug that works by blocking a specific receptor in the brain called NK1, which is involved in triggering nausea. This blockade could help prevent or reduce the intense nausea associated with motion sickness for travelers.
A multi-center, randomized, double-blind, placebo-controlled study to investigate the efficacy of tradipitant in subjects affected by motion sickness during travel
Source: ClinicalTrials.gov